Genetic LifeSpan adds cardiologist Ernst von Schwarz to scientific board

Genetic LifeSpan named cardiologist Dr. Ernst von Schwarz to its Scientific Advisory Board on June 22, 2026, as the company pushes deeper into predictive cardiovascular health. The appointment is meant to guide development of MyHeartCode™, a biomarker-based heart health platform the company says is central to its precision health strategy.

Why it matters: - Genetic LifeSpan is using medical expertise to strengthen MyHeartCode™, its cardiovascular intelligence platform. - The appointment supports the company’s broader push from reactive care toward predictive, personalized health insights. - MyHeartCode™ is positioned as a core offering in Genetic LifeSpan’s expanding diagnostics and wellness ecosystem.

What happened: - Genetic LifeSpan announced that Dr. Ernst von Schwarz has joined its Scientific Advisory Board. - The announcement was made June 22, 2026, from Incline Village, Nevada. - Dr. von Schwarz will help guide cardiovascular health initiatives and the development and integration of MyHeartCode™. - Genetic LifeSpan described Dr. von Schwarz as a globally recognized cardiologist, longevity medicine expert and preventive healthcare leader.

The details: - MyHeartCode™ is a next-generation cardiovascular intelligence platform designed to assess critical biomarkers and deliver deeper insight into cardiovascular system health. - The platform uses advanced biomarker analysis to evaluate cardiovascular function beyond traditional screening methods. - Genetic LifeSpan says the test can identify early indicators of cardiovascular stress and dysfunction. - The company says the goal is to support proactive, personalized health strategies. - Adam Vincent Gilmer, founder and CEO of Genetic LifeSpan, said Dr. von Schwarz’s knowledge in cardiovascular health and longevity science will help the company expand its platform and build out its biological intelligence infrastructure. - Dr. von Schwarz said MyHeartCode™ could redefine how cardiovascular health is understood and managed by using advanced biomarker analysis. - Genetic LifeSpan said Dr. von Schwarz’s addition strengthens its commitment to world-class scientific leadership. - The company’s broader portfolio includes epigenetic testing, biological age analysis and targeted nutraceutical solutions. - Genetic LifeSpan describes itself as a precision health and biological intelligence company focused on advanced testing, actionable insights, practitioner-guided wellness programs and personalized health solutions. - The company says its ecosystem combines genetics, epigenetics, cardiovascular intelligence, biological age assessment, preventative health technologies and data-driven wellness strategies. - Genetic LifeSpan listed its website at More information.

Between the lines: - The appointment gives Genetic LifeSpan outside medical credibility as it tries to scale a heart health product around early detection and prevention. - The company is framing MyHeartCode™ as part of a larger shift in healthcare toward earlier insights and long-term optimization, not just disease management. - The focus on biomarkers and prevention suggests Genetic LifeSpan is targeting consumers and practitioners looking for more personalized risk assessment tools.

What's next: - Genetic LifeSpan said MyHeartCode™ will continue to serve as a cornerstone of its cardiovascular intelligence offering. - Dr. von Schwarz is expected to support the platform’s continued development as the company expands its diagnostics portfolio. - The company is likely to keep building around genetic, epigenetic and cardiovascular testing as part of its health platform strategy.